Show/hide main menu

Profiles

Greg Mullen

Senior Lecturer in Imaging Biology / Radiopharmaceutics

140x180pxGregMullenEmail: greg.mullen@kcl.ac.uk

Qualifications

PhD  (Chemistry)  PhD Title: Technetium and Rhenium Thioether Complexes , The University of Kent

BSc  (Chemistry with a year Switzerland) (II.I) The University of Kent

Biography

Dr Mullen did his undergraduate and obtained his PhD in chemistry at the University of Kent in Canterbury, in 1998. His PhD involved identifying facile synthetic routes to low oxidation state technetium and rhenium radiopharmaceuticals. He went on to the Inorganic Chemistry Laboratory (ICL) at the University of Oxford to work as a postdoctoral research fellow with Prof. Jon Dilworth on rhenium and technetium chemistry. He went on to propose a theoretical selectivity mechanism for copper based hypoxia imaging agents. In 2001, Dr. Mullen then went to the National Institutes of Health (NIH) in the USA as post doctoral research fellow. He worked with David Davis and David Segal in Laboratory of Molecular Biology (LMB) in the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and Experimental Immunology Branch (EIB) in National Cancer Institute, respectively. He worked on toll like receptors and related adapter proteins and went on to propose a theoretical molecular structure of the extracellular domain of toll-like receptors. He went on to become a staff scientist in the Malaria Vaccine Development Branch in the National Institutes of Allergy and Infectious Disease where he was part of the team that took novel malaria vaccines from bench to bedside.  This included CGMP production, preclinical evaluation, preparation of Investigational New Drug (IND) applications made effective by the US FDA regulatory and coordination of US, Australian and African field trials of candidate vaccines in adults and pediatric populations.

Research interests

Areas of research: Transplantation, Immunology, Cancer, Cardiovascular and Asthma.

Research interests focus on development of diagnostic biomarkers (peptides, proteins, immune cells) for the investigation of the pathophysiology of disease (cardiovascular disease, autoimmunity, cancer) as well as investigating the underlying mechanism of action of vaccines through the use of non-invasive whole body imaging techniques, eg PET, SPECT and/or MR.

Group members

  • Adam Badar, Development of molecular imaging agents for activated complement in ischemia reperfusion injury
  • Putthiporn Charoenphun, Development of PET cell labeling agents
  • Kazumi Chia, Hypoxia imaging in cancer
  • Sarah De Freitas, Development of molecular imaging agents for antibody mediated transplant rejection
  • Seckou Diocou, The role of cancer stem cells in tumor metastases
  • Alexander O'neill, Development of a molecular agent for the imaging of macrophages in inflammation
  • Ehsan Sharif-Paghaleh The role of T regulatory cells in the induction of transplant tolerance
  • Istvan Szanda, Development of a preclinical PET scanner and PET quantification.
  • Jennifer Williams Development of amino acid moieties for site specific labeling of proteins
  • Barbara Sawyer Development of a clinical imaging biomarker for asthma
  • Joanna Lukawska Development of a clinical imaging biomarker for asthma

Teaching responsibility

  • Module convener, Graduate admissions tutor and Chair of the programme board of examiners for the following programmes:
  • MSc in Radiopharmaceuticsand PET radiochemistry
  • MRes in Medical Imaging Sciences

 

Find out more

internaladd1
Sitemap Site help Terms and conditions Accessibility Recruitment News Centre Contact us

© 2014 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454